Johnson & Johnson has agreed to pay approximately $117 million to settle allegations that it deceptively promoted transvaginal surgical mesh devices, U.S. state attorneys general said on Thursday.
The settlement resolves a multistate probe that found J&J violated consumer safety laws by misrepresenting the safety and effectiveness of its units and failing to adequately disclose risks related to their use, the attorneys general stated.
Thousands of women have sued the corporate and its Ethicon unit, alleging that they were injured by its pelvic mesh devices that are used to treat bladder problems and pelvic organ prolapse, in which organs shift from their regular positions.
A trial in California’s case concluded in September, though a decision has not yet been issued. The state of Washington settled a similar situation back in April for $9.9 million.
J&J, in a statement on Thursday, stated the settlement contains no admission of liability or wrongdoing on the part of Ethicon.
Earlier this year, the U.S. Food and Drug Administration (FDA) ordered makers of all implants to instantly stop their sale and delivery amid claims that they caused pain, breaks, urinary issues, bleeding, and other critical injuries.
J&J in 2012 stopped selling mesh implants for pelvic organ prolapse, although it continues to sell devices to be used in treating indulgence.
J&J shares have been under pressure this year, extensively underperforming the S&P healthcare sector, as the company faces numerous lawsuits alleging misleading promotion and harm from side effects brought on by its products, together with baby powder, opioid drugs, and medical devices.